Physician profile
Murliya Gowda
NPI 1548361033
$683.98
in general payments reported to CMS, 2019-2025
12 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $55.50 · 2021: $41.82 · 2022: $88.08 · 2023: $122 · 2024: $65.69 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $152.84 | 2019-2025 | Dovato |
| Theratechnologies INC. | $105.33 | 2019-2023 | Trogarzo, Egrifta |
| Gilead Sciences, INC. | $96.41 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $91.00 | 2019-2025 | Pifeltro, Capvaxive |
| Insmed, INC. | $78.15 | 2022-2024 | Arikayce |
| Smith+Nephew, INC. | $36.10 | 2020-2021 | |
| La Jolla Pharmaceutical Company | $27.40 | 2025 | Zevtera |
| Aimmune Therapeutics, INC. | $25.75 | 2025 | Vowst |
| Shionogi INC | $18.67 | 2025 | Fetroja |
| Janssen Biotech, INC. | $18.07 | 2023 | Symtuza |
| Melinta Therapeutics, LLC | $17.22 | 2025 | Rezzayo |
| Janssen Scientific Affairs, LLC | $17.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murliya Gowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.